Sermo Survey: 81% of Physicians Say Technical Proficiency is Equal to Clinical Expertise

Sermo Survey: 81% of Physicians Say Technical Proficiency is Equal to Clinical Expertise The 37th Barometer report from Sermo, a leading platform for healthcare professional (HCP) engagement offering real-time business insights and genuine physician interactions, revealed that 81% of physicians…

Read MoreSermo Survey: 81% of Physicians Say Technical Proficiency is Equal to Clinical Expertise

QGenda Simplifies Credentialing at MyMichigan Health to Boost Efficiency and Patient Access

QGenda Simplifies Credentialing at MyMichigan Health to Boost Efficiency and Patient Access QGenda, a top provider of healthcare workforce management solutions, has announced that MyMichigan Health has adopted QGenda Credentialing to enhance operational efficiency, reduce credentialing time, and improve the…

Read MoreQGenda Simplifies Credentialing at MyMichigan Health to Boost Efficiency and Patient Access

ImmunoPrecise Antibodies Announces Restructuring of Management Team

ImmunoPrecise Antibodies Announces Restructuring of Management Team ImmunoPrecise Antibodies (IPA) (NASDAQ: IPA), an AI-driven biotherapeutics discovery and technology company, is excited to share several important leadership changes. Kamil Isaev has been appointed to the Company’s Board of Directors, and Joseph…

Read MoreImmunoPrecise Antibodies Announces Restructuring of Management Team

C2N Diagnostics’ PrecivityAD2™ Blood Test Gets MHRA Certification in the UK

C2N Diagnostics’ PrecivityAD2™ Blood Test Gets MHRA Certification in the UK C2N Diagnostics, LLC, a leader in advanced brain health diagnostic testing, today announced that its PrecivityAD2™ blood test has received medical device registration from the United Kingdom’s Medicines and…

Read MoreC2N Diagnostics’ PrecivityAD2™ Blood Test Gets MHRA Certification in the UK

Seqfirst-neo Study Highlights Impact of Genomic Testing in NICU, Exposing Gaps in Protocols

Seqfirst-neo Study Highlights Impact of Genomic Testing in NICU, Exposing Gaps in Protocols GeneDx (Nasdaq: WGS), a leading provider of genomic insights aimed at improving health outcomes, announced today that the American Journal of Human Genetics has published peer-reviewed research…

Read MoreSeqfirst-neo Study Highlights Impact of Genomic Testing in NICU, Exposing Gaps in Protocols
Legends

Memphis Extends Talkspace Partnership, Expands Mental Health Services to Dependents 13+

Memphis Extends Talkspace Partnership, Expands Mental Health Services to Dependents 13+ Talkspace (NASDAQ: TALK), a leading online behavioral healthcare company, announced it will continue supporting the City of Memphis for a fifth consecutive year by providing free virtual therapy and…

Read MoreMemphis Extends Talkspace Partnership, Expands Mental Health Services to Dependents 13+

Scale Biosciences Unveils Five Single Cell Profiling Products for Scalable RNA Studies

Scale Biosciences Unveils Five Single Cell Profiling Products for Scalable RNA Studies Scale Biosciences (Scale Bio™), a leader in scalable single cell analysis, has announced the launch of its QuantumScale Single Cell RNA kits. These next-generation products are designed to…

Read MoreScale Biosciences Unveils Five Single Cell Profiling Products for Scalable RNA Studies

Median Technologies to Present eyonis™ LCS AI Software for Lung Cancer Screening at ECR

Median Technologies to Present eyonis™ LCS AI Software for Lung Cancer Screening at ECR Median Technologies, a leader in artificial intelligence (AI)-powered software for early cancer diagnostics, has announced its participation in the 2025 European Congress of Radiology (ECR) in…

Read MoreMedian Technologies to Present eyonis™ LCS AI Software for Lung Cancer Screening at ECR

PepGen Announces Positive Results from FREEDOM-DM1 Trial in DM1 Patients

PepGen Announces Positive Results from FREEDOM-DM1 Trial in DM1 Patients PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide therapies, recently announced promising early results from the ongoing FREEDOM-DM1 Phase 1 trial. The trial is investigating…

Read MorePepGen Announces Positive Results from FREEDOM-DM1 Trial in DM1 Patients